Molecular pharmacodynamics of emixustat in protection against retinal degeneration.

@article{Zhang2015MolecularPO,
  title={Molecular pharmacodynamics of emixustat in protection against retinal degeneration.},
  author={Jianye Zhang and Philip D Kiser and Mohsen Badiee and Grazyna Palczewska and Zhiqian Dong and Marcin Golczak and Gregory P Tochtrop and Krzysztof Palczewski},
  journal={The Journal of clinical investigation},
  year={2015},
  volume={125 7},
  pages={
          2781-94
        }
}
Emixustat is a visual cycle modulator that has entered clinical trials as a treatment for age-related macular degeneration (AMD). This molecule has been proposed to inhibit the visual cycle isomerase RPE65, thereby slowing regeneration of 11-cis-retinal and reducing production of retinaldehyde condensation byproducts that may be involved in AMD pathology. Previously, we reported that all-trans-retinal (atRAL) is directly cytotoxic and that certain primary amine compounds that transiently… CONTINUE READING
4
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Rational Tuning of Visual Cycle Modulator Pharmacodynamics.

  • The Journal of pharmacology and experimental therapeutics
  • 2017
VIEW 13 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS

Retinoids and Retinal Diseases.

  • Annual review of vision science
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration.

  • Biochimica et biophysica acta. Molecular basis of disease
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 72 REFERENCES

Two-photon microscopy reveals early rod photoreceptor cell damage in light-exposed mutant mice.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2014
VIEW 10 EXCERPTS